1.1.1 - Age-Related PK Changes

1.1.1.3 Foundational PK framework: what changes, what does not

A Explanation

The first exam decision conflict is this: when an older adult has a medication problem, should you blame absorption, or should you focus on distribution, metabolism, and excretion? The correct choice is usually to reject absorption as the main culprit unless the stem gives a specific reason such as achlorhydria affecting a pH-dependent drug, enteral feed interaction, constipation/ileus, malabsorption, or administration error. Aging alone produces variable absorption changes, but the biggest clinically actionable shifts are usually reduced renal clearance, altered body composition, and reduced hepatic blood flow.

WHY THIS IS TESTED: exam stems often include many age-related physiologic facts, but only one explains why a usual dose becomes unsafe. The tested pattern is choosing the PK domain that actually changes the concentration-time curve in a meaningful way.

Use a simple hierarchy. First ask: does the drug depend on kidney clearance? If yes, renal change often dominates. If not, ask whether the drug is lipophilic or hydrophilic, then whether hepatic oxidative metabolism is important. Maintenance dosing tracks clearance; loading dose tracks distribution. So if the issue is a higher peak with an aminoglycoside, think reduced total body water and altered Vd. If the issue is prolonged sedation with diazepam, think increased fat stores and longer half-life. If the issue is accumulation of digoxin or gabapentin, think reduced renal elimination.

flowchart TD
A[Older adult with possible drug toxicity] --> B{Which PK domain best explains it?}
B --> C[Renal elimination reduced]
B --> D[Distribution altered by less water and more fat]
B --> E[Hepatic Phase I metabolism reduced]
B --> F[Absorption change only if stem gives specific clue]
C --> G[Lower dose or extend interval]
D --> H[Hydrophilic higher peak or lipophilic prolonged effect]
E --> I[Watch high extraction and oxidized drugs]
F --> J[Check administration, pH, feeds, GI disease]

B Worked example

An 84-year-old woman in assisted living is reviewed after increased morning confusion. Her medications include diazepam 5 mg by mouth nightly, metoprolol succinate 50 mg daily, calcium carbonate 500 mg three times daily, and omeprazole 20 mg daily. She has osteoarthritis and chronic constipation. Serum creatinine is 0.8 mg/dL, BP 126/68 mm Hg, and there is a note that she sometimes takes her medications with yogurt. The team asks which age-related PK change best explains the prolonged sedation.

Identify task: choose the most likely PK change producing toxicity. Extract key facts: lipophilic benzodiazepine, nightly dosing, morning carryover, no clear renal injury signal, distracting clue is calcium/omeprazole/yogurt suggesting absorption interactions. Apply rule: diazepam is highly lipophilic; increased body fat increases Vd and prolongs half-life. Eliminate distractors: reduced gastric acidity can alter absorption of some drugs, but not the best explanation for next-day sedation with diazepam. “Normal” serum creatinine is irrelevant here because diazepam toxicity is not mainly from renal accumulation. Verify: safest pharmacist recommendation is to flag the long-acting benzodiazepine and suggest taper/alternative rather than focusing on food administration.

C Exam trap

D Checkpoint

Question: Which age-related PK change most often explains why standard adult maintenance doses become unsafe in older adults?

1. Marked loss of oral absorption for most medications
2. Reduced renal clearance despite apparently normal serum creatinine
3. Universal increase in Phase II hepatic conjugation
4. Consistent increase in first-pass metabolism for all high-extraction drugs

Answer: B

• A: Tempting because GI physiology changes with age, but most drugs are still adequately absorbed; absorption alone is not the main high-yield explanation.
• B: Correct because age-related decline in kidney function is common and clinically important for maintenance dosing and toxicity prevention.
• C: Tempting if you remember Phase II is often preserved, but it is not universally increased.
• D: Tempting if you associate aging with liver changes, but first-pass metabolism does not consistently increase; if anything, reduced blood flow may increase bioavailability for some high-extraction drugs.

1.1.1.4 Distribution changes: less water, more fat, different peaks and half-lives

A Explanation

The decision conflict here is whether to adjust because a drug is hydrophilic or because it is lipophilic. The single rule that resolves it is body composition: older adults generally have reduced total body water and lean body mass plus increased body fat percentage. Hydrophilic drugs have a smaller Vd, so a standard dose can yield a higher plasma concentration. Lipophilic drugs have a larger Vd, so they redistribute into fat and may have a longer terminal half-life with prolonged effects.

WHY THIS IS TESTED: board stems often ask why one older adult gets a higher peak concentration while another gets prolonged sedation. The tested pattern is matching drug physicochemical behavior to age-related body composition.

High-yield examples: aminoglycosides, ethanol, and lithium are relatively hydrophilic; diazepam is classically lipophilic. Digoxin also deserves special care because reduced lean body mass can reduce Vd, increasing serum concentration sensitivity, though kidney function is also crucial. This means loading doses and initial dose selection may change for hydrophilic drugs, while interval or maintenance strategy often changes for lipophilic drugs with long half-lives. The exam may also combine low body weight or cachexia with aging, which strengthens the hydrophilic concentration effect further.

Do not overgeneralize: not every lipophilic drug must be avoided, and not every hydrophilic drug needs a lower dose. The question is whether the observed toxicity pattern fits a Vd problem. Fast toxicity after a standard loading dose suggests smaller Vd for a water-soluble drug. Slow accumulation with persistent sedation suggests larger fat distribution and delayed elimination.

B Worked example

A 79-year-old man in a skilled nursing facility receives gentamicin 5 mg/kg IV as part of a facility protocol pending prescriber review for gram-negative bacteremia. He has frailty, heart failure, and chronic kidney disease; weight is 54 kg. He also takes furosemide 40 mg daily and sertraline 50 mg daily. The nurse notes dizziness after the first dose. Serum creatinine is 1.0 mg/dL, which is close to his baseline. The pharmacist is asked which age-related PK principle should guide the immediate dosing review.

Identify task: choose the governing PK change. Extract key facts: hydrophilic drug, low body weight, frailty, older adult, possible higher concentration after initial dose. Ototoxic loop diuretic is a distracting but relevant risk amplifier, not the core PK principle. Apply rule: reduced total body water and lean mass can shrink Vd for hydrophilic drugs, increasing peak concentration. Eliminate distractors: increased body fat explains lipophilic drug prolongation, not aminoglycoside early peak concerns. Reduced gastric acidity is irrelevant because the drug is IV. Verify: this patient also needs renal assessment and careful serum-level strategy, but the first-dose concentration problem is distribution-based.

C Exam trap

D Checkpoint

Question: Which drug is most likely to have a prolonged half-life in an older adult primarily because of increased body fat?

1. Diazepam
2. Gentamicin
3. Lithium
4. Atenolol

Answer: A

• A: Correct because diazepam is lipophilic and distributes into fat, prolonging its effect.
• B: Tempting because gentamicin toxicity is common in older adults, but its major issue is hydrophilic distribution and renal clearance, not fat-related prolongation.
• C: Tempting because lithium is narrow therapeutic index, but it is not the classic fat-distribution example.
• D: Tempting because atenolol can accumulate in kidney impairment, but prolonged half-life from increased body fat is not the main mechanism.

1.1.1.5 Hepatic metabolism: reduced blood flow, reduced Phase I, preserved Phase II

A Explanation

The exam conflict here is whether aging reduces all hepatic metabolism equally. Reject that oversimplification. The single rule is that hepatic blood flow and liver mass tend to decline with age, and Phase I oxidative metabolism is more affected than Phase II conjugation. This matters most for drugs with significant first-pass extraction or reliance on oxidative clearance. As a result, some drugs may have increased bioavailability or reduced clearance, especially when hepatic extraction and blood flow are important.

WHY THIS IS TESTED: the stem may ask why an older adult has greater effect from an oral dose or why a sedative lasts longer even without kidney failure. The testable pattern is choosing reduced Phase I metabolism or reduced hepatic blood flow rather than assuming global liver failure.

Examples matter. Diazepam is a classic Phase I example and can have prolonged effects. Lorazepam, oxazepam, and temazepam are often favored when a benzodiazepine is unavoidable because they rely more on conjugation. This does not make them harmless in older adults; it just explains why some short-acting conjugated agents are pharmacokinetically preferable to long-acting oxidized ones. Similarly, high-extraction drugs may show higher oral bioavailability if first-pass extraction falls. On the exam, you are not expected to turn every liver-metabolized drug into a memorization list. You are expected to recognize the pattern: Phase I is more vulnerable than Phase II.

flowchart LR
A[Aging liver changes] --> B[Reduced liver mass]
A --> C[Reduced hepatic blood flow]
A --> D[Phase I oxidation reduced more]
A --> E[Phase II conjugation relatively preserved]
D --> F[Longer effect for oxidized drugs]
C --> G[Higher bioavailability for some high-extraction drugs]
E --> H[Conjugated options may be PK-preferred]

B Worked example

An 81-year-old woman in primary care is taking diazepam 2 mg by mouth twice daily as needed for muscle spasm after a hospitalization. Comorbidities include osteoporosis, chronic insomnia, and mild heart failure. She reports daytime grogginess and one near-fall. Serum creatinine is 0.7 mg/dL, AST/ALT are normal, and she asks whether “her liver tests being normal” means the dose is fine. A tempting clue is that she also takes omeprazole, which may suggest an interaction-focused answer.

Identify task: determine the age-related PK principle behind prolonged effect. Extract key facts: oxidatively metabolized long-acting benzodiazepine, older adult, grogginess and near-fall, normal transaminases. Apply rule: age-related hepatic blood flow reduction and reduced Phase I metabolism can prolong diazepam effect even when routine liver tests are normal. Eliminate distractors: a normal AST/ALT does not rule out reduced functional clearance with aging. Omeprazole may interact with some agents, but the core tested principle is physiologic aging of hepatic metabolism. Verify: recommend deprescribing discussion or alternative therapy with safer risk profile, not reassurance based on liver tests.

C Exam trap

D Checkpoint

Question: Which statement best supports selecting lorazepam over diazepam when a benzodiazepine cannot be avoided in an older adult?

1. Lorazepam is not associated with falls in older adults
2. Lorazepam has no hepatic metabolism
3. Lorazepam relies more on conjugation, which is relatively preserved with aging
4. Diazepam is safer because its lipophilicity prevents accumulation

Answer: C

• A: Tempting because lorazepam is often viewed as safer, but all benzodiazepines still increase fall and cognitive risk.
• B: Tempting because “LOT” is a famous memory aid, but lorazepam is hepatically handled; it is not free of hepatic metabolism.
• C: Correct because conjugation is relatively preserved compared with oxidative metabolism in aging.
• D: Tempting if you misremember lipophilicity as protective, but lipophilicity contributes to diazepam’s prolonged half-life in older adults.

1.1.1.6 Renal elimination: the serum creatinine trap and dosing decisions

A Explanation

This is the highest-yield section for the BCGP exam. The decision conflict is whether a “normal” serum creatinine means kidney function is adequate for dosing. The single rule that resolves it is that serum creatinine reflects both filtration and muscle mass. Older adults often have reduced muscle mass, so serum creatinine can look normal even when true filtration is reduced. For medication dosing, the exam usually expects you to think in terms of estimated creatinine clearance using Cockcroft-Gault, because many drug labels and studies use it.

WHY THIS IS TESTED: many wrong answers occur because learners equate SCr 0.8 mg/dL with “normal kidneys.” The testable pattern is recognizing hidden renal impairment in a small, frail, older adult.

Key consequence: maintenance dosing of renally cleared drugs may need a lower dose, longer interval, or both. High-yield examples include digoxin, DOACs, gabapentin, pregabalin, metformin, aminoglycosides, and many antimicrobials. Also distinguish chronic age-related decline from acute kidney injury. Aging lowers reserve; dehydration, diuretics, infection, ACE inhibitors, NSAIDs, or contrast can push the patient into a more dangerous range quickly. The exam may ask what requires immediate clarification: it is often a newly started renally cleared drug at a standard dose in a frail older adult with low body weight and “normal” SCr.

Do not automatically round low serum creatinine values upward without a specific local protocol; that practice can misestimate function and is not universally recommended. Use an evidence-based approach and the dosing method tied to the drug reference or label.

flowchart TD
A[Older adult on renally cleared drug] --> B[Check age, weight, baseline SCr, hydration]
B --> C{Is SCr deceptively normal?}
C --> D[Yes: low muscle mass may mask reduced function]
C --> E[No: still estimate dosing function]
D --> F[Use Cockcroft-Gault or drug-specific dosing standard]
E --> F
F --> G{Drug has renal cutoff?}
G --> H[Adjust dose or interval]
G --> I[Monitor and reassess if no adjustment needed]

B Worked example

An 88-year-old woman is discharged from the hospital to home with apixaban 5 mg by mouth twice daily for atrial fibrillation, gabapentin 300 mg by mouth three times daily for neuropathy, and lisinopril 10 mg daily. She weighs 47 kg, has hypertension and mild cognitive impairment, and uses a walker. Serum creatinine today is 0.8 mg/dL; last week she had poor oral intake after influenza. The pharmacist performing discharge reconciliation is asked what requires immediate clarification.

Identify task: prioritize the PK risk needing pharmacist action. Extract key facts: very old age, low body weight, frailty signal, renally relevant medications, apparently normal SCr, recent dehydration as distracting acute factor. Apply rule: SCr may overestimate kidney function; renally relevant regimens require dose review using the appropriate dosing standard. Eliminate distractors: lisinopril may need monitoring, but the most urgent clarification is whether apixaban and gabapentin doses fit current renal function and patient-specific criteria. Verify: recommend CrCl-based dose review, confirm weight and age criteria, reassess renal function after discharge, and monitor bleeding/sedation.

C Exam trap

D Checkpoint

Question: A frail 86-year-old woman weighing 45 kg has serum creatinine 0.7 mg/dL and is prescribed a standard dose of a renally eliminated medication. What is the most appropriate pharmacist recommendation?

1. Assume renal function is normal because serum creatinine is below 1 mg/dL
2. Estimate CrCl using the dosing-standard method and assess whether dose or interval adjustment is needed
3. Ignore kidney function and reduce the dose only because of age
4. Increase the dose because low serum creatinine suggests augmented clearance

Answer: B

• A: Tempting because reference ranges can falsely reassure, but low muscle mass can mask renal impairment.
• B: Correct because dosing should be tied to an appropriate estimate of renal function, commonly Cockcroft-Gault for drug dosing.
• C: Tempting because “start low” is common in geriatrics, but dosing should be individualized rather than reduced solely by chronological age.
• D: Tempting only if one misunderstands the creatinine trap; low SCr in frailty does not imply augmented clearance.

1.1.1.7 Integration: translating PK changes into safer geriatric medication decisions

A Explanation

The final conflict is practical: when a board stem shows possible PK risk, should you recommend a lower dose, a longer interval, an alternative medication, or more monitoring? The single rule is to match the intervention to the PK problem. If the drug has a smaller Vd in aging and the issue is high peak concentration, consider a lower initial or loading dose. If the issue is reduced clearance and longer half-life, adjust the maintenance dose, extend the interval, or both. If the problem is persistent toxicity from a long-acting or high-risk drug, selecting an alternative may be safer than “micro-adjusting” the same agent.

WHY THIS IS TESTED: the exam is not satisfied with recognizing the PK change; it asks whether you can make a pharmacist-level recommendation that is safe, specific, and within scope.

Use a structured approach. First, identify whether the harm is concentration-related, duration-related, or interaction-amplified. Second, assess whether the drug is high value, replaceable, or inappropriate for geriatric use. Third, choose the narrowest effective intervention: adjust dose, adjust interval, slow titration, recommend a safer alternative, or deprescribe. Fourth, define monitoring tied to the expected toxicity. For example, with gabapentin accumulation, monitor sedation, dizziness, gait instability, and renal trend. With digoxin, monitor symptoms, heart rate, renal function, and if appropriate levels. With long-acting benzodiazepines, monitor confusion, falls, and withdrawal risk if tapering.

flowchart TD
A[Possible PK-related adverse effect] --> B{What pattern fits best?}
B --> C[Early high concentration]
B --> D[Delayed accumulation or prolonged effect]
B --> E[Hidden renal impairment]
C --> F[Lower initial or loading dose]
D --> G[Lower maintenance dose or extend interval]
E --> H[Recalculate dosing function and adjust]
F --> I{Drug still appropriate?}
G --> I
H --> I
I --> J[If not, recommend safer alternative or deprescribing]
J --> K[Set monitoring for efficacy, toxicity, withdrawal]

B Worked example

An 83-year-old man in long-term care has chronic neuropathic pain, stage 3b CKD, diabetes, and a recent fall. His MAR shows gabapentin 600 mg by mouth three times daily, trazodone 50 mg nightly, and hydrocodone/acetaminophen 5/325 mg every 6 hours as needed. He is more somnolent after supper but requests that pain therapy not be stopped completely. A recent sodium of 132 mEq/L is mildly low and may distract toward trazodone as the sole issue.

Identify task: recommend the safest pharmacist action. Extract key facts: renally cleared gabapentin at a potentially excessive dose for CKD, fall, somnolence, competing sedatives. Apply rule: clearance problem means maintenance dose or interval should be adjusted to renal function; if toxicity persists, deprescribe or switch strategy. Eliminate distractors: trazodone contributes to sedation, but the signature PK issue is gabapentin accumulation in reduced renal function. Simply adding monitoring without a dose recommendation is too passive. Verify: recommend renal dose reassessment, dose reduction or interval change per reference, sedation/fall monitoring, and communication with the prescriber/team.

C Exam trap

D Checkpoint

Question: Which recommendation best fits an older adult with toxicity from a renally cleared maintenance medication and hidden renal impairment?

1. Increase the loading dose to overcome age-related absorption changes
2. Lower the maintenance dose or extend the interval based on the drug’s renal dosing guidance
3. Keep the current dose and monitor only because serum creatinine is normal
4. Switch automatically to another drug in the same class at an equivalent standard dose without reassessing renal handling

Answer: B

• A: Tempting if one wrongly assumes poor absorption drives most geriatric toxicity, but the issue is impaired clearance.
• B: Correct because maintenance dosing must match reduced renal elimination.
• C: Tempting because “monitoring” feels safe, but it ignores the need for an active dosing correction.
• D: Tempting if the class is familiar, but an equivalent standard dose may recreate the same PK problem.